PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer

NCT07130344 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

262

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer
HER 2 Low-expressing Breast Cancer

Interventions

PROCEDURE: TAP CT-scan
PROCEDURE: Bone scintigraphy
PROCEDURE: 18F-FDG PET-CT

Sponsor

Centre Paul Strauss